BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI), today announced that it has
received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO)
for its patent application titled "Use of P97 as an Enzyme Delivery System for
the Delivery of Therapeutic Lysosomal Enzymes", US Patent Application Number
12/729,792. The Notice of Allowance is the USPTO's official communication that
the Company's application has successfully completed examination and that a
patent will be issued upon final review and payment of the issue fee. The
addition of this new patent to biOasis' growing intellectual property portfolio
will be another key value component of biOasis drug development efforts focused
on developing valuable therapies to address important unmet medical needs. 


The allowed claims of this patent application cover methods of using the
Company's Transcend brain penetrating drug delivery vector coupled to a
lysosomal storage disease enzyme for the treatment of lysosomal storage
diseases. Specifically, the enzymes claimed in the allowed patent application
include those that are used clinically as enzyme replacement therapies to treat
lysosomal storage diseases such as Hunter Syndrome, Hurler syndrome and others. 


ABOUT LYSOSOMAL STORAGE DISEASES

Lysosomal storage diseases are inherited metabolic disorders caused by a
deficiency in lysosomal enzymes, of which approximately fifty have been
described to date. These diseases usually affect children, many of whom die
within several years of birth and some following years of dealing with symptoms
of the disease that may include developmental delay, movement disorders,
seizures, dementia, deafness and blindness. The most effective therapeutic
strategy is for replacement of the missing enzyme. However, no currently
approved therapeutic enzyme is able to effectively treat the effects of these
diseases on the central nervous system. Despite the limitations of existing
products, market revenues have exceeded $2 billion for each of the past three
years. 


ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward Looking Statements 

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors 

Rob Hutchison Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024